Stock Details
NVS is Novartis AG's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 86.37$. Average daily volumn in 3 months 2.29M. Market cap 195.00B



Stock symbol : NVS. Exchange : NYSE. Currency : USD
Lastest price : 92.00$. Total volume : 1.66M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Novartis AG (NVS)
Last Price
92.00$
Change
0.42
Volume
1.66M

Previous Close91.58
Open91.78
Day Range91.65-92.19
Bid91.01 x 800
Ask92.41 x 800
Volume1.66M
Average Volume2.29M
Market Cap195B
Beta0.46
52 Week Range74.09-94.26
Trailing P/E29.02
Foward P/E12.92
Dividend (Yield %)3.80%
Ex-Dividend Date2023-03-09



Financial Details


According to Novartis AG's financial reports the company's revenue in 2022 were 51.83B an decrease(-1.92%) over the years 2021 revenue that were of 52.88B. In 2022 the company's total earnings were 6.96B while total earnings in 2021 were 24.02B(-75%).


Loading ...



Organization

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceu... ticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Market Cap:
195.00B
Revenue:
51.83B
Total Assets:
117.45B
Total Cash:
7.52B



News about "Novartis AG"

Novartis AGโ€™s (NVS) Stock: A 7.78% Simple Moving Average for the Past 20 Days

Source from : newsheater - 3 days ago

The stock of Novartis AG (NVS) has seen a 10.04% increase in the past week, with a 7.22% gain in the past month, and a -1.03% decrease in the past quarter. The volatility ratio for the week is 1.24%, ...See details»


Before You Sell Novartis AG (NYSE: NVS) Shares, Hereโ€™sWhat You Need To Know.

Source from : stocksregister - 7 days ago

Novartis AG (NYSE:NVS) shares, rose in value on Friday, 03/24/23, with the stock price up by 1.31% to the previous dayโ€™s close as strong demand from buyers drove the stock to $83.59. Actively ...See details»


Novartis AG

Source from : Wall Street Journal - 4 days ago

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»


Novartis Pharma AG: Novartis Entresto receives positive CHMP opinion for pediatric heart failure

Source from : Finanznachrichten - 1 days ago

If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to Pediatric heart failure is an important cause ...See details»


Novartis AG (NVS) Stock: A Study of the Market Performance

Source from : newsheater - 10 days ago

NVS stock has gone down by -0.17%, with a monthly decline of -5.53% and a quarterly plunge of -9.13%. The volatility ratio for the week is 1.28%, and the volatility levels for the last 30 days are ...See details»


Novartis AG: Novartis Posts Strong Kisqali Top-Line Data in Large Adjuvant Treatment Setting

Source from : Yahoo Finance - 5 days ago

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment ...See details»


Novartis AG (NVS) Stock Rises on Plan to Increase Profit Margin

Source from : TheStreet.com - 1 month ago

TheStreet Ratings team rates NOVARTIS AG as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation: "We rate NOVARTIS AG (NVS) a BUY. This is based on ...See details»


Why Novartis Shares Are Trading Higher Premarket Today

Source from : Yahoo Finance - 5 days ago

Novartis AG (NYSE: NVS) shares are trading higher in the premarket session after its breast cancer drug showed clinical benefit in early-stage breast cancer. Novartis announced topline results ...See details»


Short Volatility Alert: Novartis Ag

Source from : Benzinga.com - 24 days ago

On Wednesday, shares of Novartis Ag NVS experienced volatile short activity. After the activity, the stock price went down -0.82% to $83.29. The overall sentiment for NVS has been Bearish.See details»


Novartis AG (NYSE:NVS) Q4 2022 Earnings Call Transcript

Source from : Yahoo - 1 month ago

Novartis AG (NYSE:NVS) Q4 2022 Earnings Call Transcript February 1, 2023 Operator: Good morning and good afternoon, and welcome to the Novartis Q4 2022 Results Release Conference Call and Live ...See details»


Novartis Scraps Crucial Study as UK Scrambles to Revive Trials

Source from : Bloomberg L.P. on MSN - 11 days ago

Novartis AG is scrapping a high-profile UK clinical trial once touted as an example of National Health Service collaboration, even as the government tries to smooth the path for other studies and ...See details»


east-hanover-board-rejects-novartis-proposal-to-subdivide-17-acres-of-its-campus-for-sale-image

East Hanover board rejects Novartisโ€™ proposal to subdivide 17 acres of its campus for sale

Source from : New Jersey Hills - 2 days ago

The East Hanover Land Use Planning Board unanimously voted Thursday, March 23 to deny an application by Novartis to subdivide about 17 acres of its campus near the Florham Park ...See details»


Novartis shares jump on breast cancer drug trials success

Source from : Fox Business - 6 days ago

Shares for Novartis are up on Monday after the Swiss pharma company reported positive trial data for its breast-cancer treatment Kisqali. Analysts from Jefferies said the report could represent a ...See details»


Novartis Pharma AG: Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Source from : Finanznachrichten - 26 days ago

Amendment of the Articles of Incorporation Shareholders also approved the Board of Directors' proposal for the amendment of the Articles of Incorporation of Novartis AG implementing the ...See details»